% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Eichenauer:278409,
      author       = {D. A. Eichenauer and I. Bühnen and C. Baues and C. Kobe
                      and H. Kaul and R. Greil and A. Moccia and J. M. Zijlstra
                      and B. Hertenstein and M. S. Topp and M. Just and B. von
                      Tresckow$^*$ and H.-T. Eich and M. Fuchs and M. Dietlein and
                      S. Hartmann and A. Engert and P. Borchmann},
      title        = {{I}nterim {PET}-guided treatment for early-stage {NLPHL}: a
                      subgroup analysis of the randomized {GHSG} {HD}16 and {HD}17
                      studies.},
      journal      = {Blood},
      volume       = {142},
      number       = {6},
      issn         = {0006-4971},
      address      = {Washington, DC},
      publisher    = {American Society of Hematology},
      reportid     = {DKFZ-2023-01643},
      pages        = {553 - 560},
      year         = {2023},
      abstract     = {The optimal first-line treatment for nodular
                      lymphocyte-predominant Hodgkin lymphoma (NLPHL) diagnosed in
                      early stages is largely undefined. We, therefore, analyzed
                      100 NLPHL patients treated in the randomized HD16
                      (early-stage favorable; n = 85) and HD17 (early-stage
                      unfavorable; n = 15) studies. These studies investigated the
                      omission of consolidation radiotherapy (RT) in patients with
                      a negative interim positron emission tomography (iPET) (ie,
                      Deauville score <3) after chemotherapy (HD16: 2×
                      doxorubicin, bleomycin, vinblastine, and dacarbazine [ABVD];
                      HD17: 2× escalated bleomycin, etoposide, doxorubicin,
                      cyclophosphamide, vincristine, procarbazine, and prednisone
                      [BEACOPP] plus 2× ABVD). Patients with NLPHL treated in the
                      HD16 and HD17 studies had 5-year progression-free survival
                      (PFS) rates of $90.3\%$ and $92.9\%,$ respectively. Thus,
                      the 5-year PFS did not differ significantly from that of
                      patients with classical Hodgkin lymphoma treated within the
                      same studies (HD16: P = .88; HD17: P = .50). Patients with
                      early-stage favorable NLPHL who had a negative iPET after
                      2× ABVD and did not undergo consolidation RT tended to have
                      a worse 5-year PFS than patients with a negative iPET who
                      received consolidation RT $(83\%$ vs $100\%;$ P = .05).
                      There were 10 cases of NLPHL recurrence. However, no NLPHL
                      patient died during follow-up. Hence, the 5-year overall
                      survival rate was $100\%.$ Taken together, contemporary
                      Hodgkin lymphoma-directed treatment approaches result in
                      excellent outcomes for patients with newly diagnosed
                      early-stage NLPHL and, thus, represent valid treatment
                      options. In early-stage favorable NLPHL, consolidation RT
                      appears necessary after 2× ABVD to achieve the optimal
                      disease control irrespective of the iPET result.},
      keywords     = {Humans / Hodgkin Disease: diagnostic imaging / Hodgkin
                      Disease: drug therapy / Bleomycin: adverse effects /
                      Doxorubicin / Dacarbazine / Vinblastine / Antineoplastic
                      Combined Chemotherapy Protocols: adverse effects /
                      Cyclophosphamide / Vincristine: adverse effects /
                      Positron-Emission Tomography: methods / Prednisone /
                      Bleomycin (NLM Chemicals) / Doxorubicin (NLM Chemicals) /
                      Dacarbazine (NLM Chemicals) / Vinblastine (NLM Chemicals) /
                      Cyclophosphamide (NLM Chemicals) / Vincristine (NLM
                      Chemicals) / Prednisone (NLM Chemicals)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37257195},
      doi          = {10.1182/blood.2023019939},
      url          = {https://inrepo02.dkfz.de/record/278409},
}